Asian equity markets were poised to gain on Thursday, tracking Wall Street's rally after positive trial results of an experimental COVID-19 treatment, a U.S.
Federal Reserve pledge to shore up the economy and a jump in oil prices. A top U.S. health official said Gilead Sciences Inc's antiviral drug remdesivir is likely to become the standard of care for COVID-19 after early results from a clinical trial showed it helped certain patients recover more quickly.
Investors expect the ensuing virus treatments to be critical in helping countries emerge from self-imposed lockdowns aimed at curbing the outbreak. "The markets were up on expectation of the Gilead drug meeting the clinical end point, more regional re-opening in the U.S., and